Avacincaptad pegol shows promise in treating geographic atrophy secondary to dry AMD
Complement C5 is a viable target for inhibition to potentially prevent retinal pigment epithelial cell death in patients with geographic atrophy, according to a presentation as the 2020 American Society of Retinal Specialists Meeting.
Data was from a pivotal, randomized, double masked, sham controlled clinical trial evaluating the safety and efficacy of avacincaptad pegol (Zimura) for the treatment of geographic atrophy by Baruch Kuppermann, MD, PhD.
In the trial, 286 patients were treated with either sham, avacincaptad pegol 2 mg, or avacincaptad pegol 4 mg. The primary efficacy endpoint was the mean rate of change in geographic atrophy over 12 months measured by fundus autofluorescence (FAF) at baseline, 6 months, and 12 months.
At 12 months, the reduction in the mean rate of geographic atrophy growth was 27.38% for the avacincaptad pegol 2 mg group and 27.81% for the avacincaptad pegol 4 mg group compared to their respective corresponding sham groups. Data for both dose groups was statistically significant.
The researchers concluded that the overall data suggest a dose response relationship across treatment arms.
Avacincaptad pegol was generally well tolerated with no ocular serious adverse events and no cases of endophthalmitis reported in the study eye in this ongoing trial.
Kuppermann B, et al. Avacincaptad pegol, a novel C5 inhibitor, reached statistical significance in a pivotal clinical trial for geographic atrophy secondary to dry AMD. Presented at: 2020 American Society of Retinal Specialists Meeting.